Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks
Who should avoid GLP-1 receptor agonists
Researchers are actively studying these reactions to better understand why they happen and how to prevent them
For adults with type 2 diabetes and established atherosclerotic cardiovascular disease, high cardiovascular risk, chronic kidney disease, or heart failure, guidelines recommend GLP-1 agonists with proven cardiovascular benefit as preferred agents, independent of metformin use or baseline A1C
Risks arise when: Glutathione is administered in salons or wellness centres Dosages are not standardised Emergency preparedness is absent Patients are not medically screened This is why dermatologists clearly advise patients to avoid non-clinical IV glutathione treatment in Chennai , regardless of how attractive the offer appears